15 April 2024
15 April 2024
The Clinical Trials Arena team also evaluates candidates in oncology, dermatology and immunology.
At CTS New England 2024, clinical trial supply managers were called to leverage technology to reduce the risk of drug shortages in clinical trials.
The safety profile of the Columvi combination regimen was in line with the priorly reported data of the individual medicines.
The US Food and Drug Administration (FDA) has cleared Sight Sciences’ OMNI surgical system to reduce intraocular pressure in patients with primary open-angle glaucoma.
The biotech’s FPM platform uses drug screening technology, molecular profiling, and AI models to guide treatment decisions.
The FDA designation follows positive Phase II data announced recently.
The trial analysed the efficacy and safety of bexagliflozin against dapagliflozin, both in conjunction with metformin.
The trial is assessing the efficacy and safety of the immunotherapy in individuals with Type 1 Diabetes (T1D).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report offers insight into the competitive landscape of leading CGT agents in CNS disorders including launch date projections, analyst consensus forecasts, LoA analysis, and commentary on current and future players. The global CGT market in CNS disorders will experience significant growth, with sales expected to grow at a CAGR of 42.4% by 2029. Gene therapies will dominate the CGT market in CNS disorders, attributed to strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively.
GlobalData's latest report offers insight into the competitive landscape of leading CGT agents in CNS disorders including launch date projections, analyst consensus forecasts, LoA analysis, and commentary on current and future players. The global CGT market in CNS disorders will experience significant growth, with sales expected to grow at a CAGR of 42.4% by 2029. Gene therapies will dominate the CGT market in CNS disorders, attributed to strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively.
Give your business an edge with our leading industry insights.
